spacer
home > pmps > autumn 2017 > the path ahead
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Path Ahead

Falsified medicines (the term 'falsified' is used to distinguish the issue from IP violations, so-called 'counterfeits') are a major threat to public health and safety. As falsifications become more sophisticated, the risk that falsified medicines reach patients in the EU increases every year, representing a serious threat to global health and calling for a comprehensive strategy both at European and international level. The EU Commission has published on 2 October 2015, which supplements by laying down detailed rules for the safety features that appear on the packaging of medicinal products for human use. This regulation sets the characteristics and technical specifications of the unique identifier that enables the authenticity of medicinal products to be verified and individual packs to be identified. The regulation shall apply from 9 February 2019.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Graham Hughes, Consultant in Pharmaceutical Development
spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wire it with pride with Teknomeks latest modular storage options

Teknomek has extended its modular shelving range to offer customers more options to make optimal use of the storage space available to them. The hygienic units are built from 304 grade stainless steel and feature wire shelving, which does not interrupt air circulation and prevents from dust settling.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Outsourcing Clinical Trials Nordics 2018

30-31 October 2018, Copenhagen, Denmark

Following on from the success of the 2017 Outsourcing in Clinical Trials Nordics conference, Arena International is pleased to announce that the event will return for its 6th year in 2018. The 2018 event welcomes biopharmaceutical and medical device companies from across the Nordic region to share knowledge and challenges of outsourcing and clinical operations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement